JAIDS Journal of Acquired Immune Deficiency Syndromes
26:517–520 © 2001 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 26, 2001

Author Index

Aarnoutse RE, 218
Abgrall S, 151
Abrams DI, 443
Adjé C, 501
Agbalika F, 182
Alcantara LCJ, 490
Algren H, 443
Altmann D, 266
Ammassari A, 326
An P, 507
Anastos K, 28
Andia J, 164
Antinori A, 326
Appelberg R, 300
APROCO Study Group, The 480
Arkin S, 466
Augenbraun M, 28
Aung H, 305
Azzari C, 196

Ba DS, 130
Baeten JM, 360
Bahula C, 8
Bala M, 393
Bangsberg DR, 435
Bankson DD, 360
Barak Y, 111
Barbouche RM, 298
Barin F, 413
Barlow KL, 381
Barreiro P, 391
Bassène E, 130
Battegay M, 191
Becker SL, 72
Bedynek A, 225
Belda FJ, 381
Bennett CL, 390
Bentwich Z, 111
Berhane K, 28
Betts MR, 423
Biggar RJ, 371
Bissagene E, 501
Bittencourt AL, 490
Blasi E, 300
Blok WL, 218
Bloor S, 495
Boelaert JR, 300
Bogner J, 225
Bollinger R, 21
Bollinger RC, 352
Bonacini M, 340
Bonhoeffer S, 397
Booth RE, 483
Boros S, 473
Boutwell RC, 263
Brand D, 413
Briones C, 145
Brookmeyer RS, 352
Brown AE, 345
Brown G, 236
Brown T, 93
Brunet S, 413
Brunn M, 266
Buapunth P, 345
Buchanan RJ, 246
Bucher HC, 191
Burger DM, 218
Buzelay L, 413
Bwayo JJ, 360

Cadorin L, 299
Cagle HH, 515
Caldwell P, 332
Cao Y, 1
Chadapaud S, 44
Chang CJ, 291
Charlebois ED, 435
Cheingsong R, 501
Chen J, 365
Chen S-C, 274
Chen Yi-Ming A, 274
Chêne G, 480
Chernoff D, 466
Chesney M, 435
Chirenje Z, 21
Chorba T, 501
CHORUS Program Team, 72
Chouraqui M, 44
Chuang Y-C, 274
Churchill D, 462
Ciccarone D, 435
Cingolani A, 326
Clague H, 435
Clark RA, 513
Clewley JP, 381
Cliffe S, 381
Clinical Epidemiology Group from the French Hospital Database on HIV, 151
Cohen M, 28
Collier AC, 320
Colón HM, 164
Costagliola D, 130, 151
Coulaud JP, 130
Coulibaly M, 501
Coull JJ, 423

D'Angelo LJ, 449
Daar ES, 466
Damas CD, 185
Darioli R, 389
Darragh T, 256
de Goër M-G, 303
De Luca A, 326
de Martino M, 196
de Souza MS, 345
De Vroey V, 495
Deeks SG, S25
Dehertogh P, 495
DeHovitz JA, 390
del Romero J, 145
Delaporte E, 36
Delbeke E, 44
Delfraissy JF, 303
Dellagi K, 298
Demant T, 225
Demeter L, S3, S51
Demouchy C, 193
Deren S, 164
Detels R, 82
Devereux H, 159
di Gennaro G, 299
Di Lonardo AM, 193
Diagbouga S, 193
Didier J-M, 193
Dieleman JP, 218
Dieterich DT, 208
Divekar AD, 352
Djomand G, 501
Donfield S, 449, 466
Dore GJ, 283
Dorrucci M, 377
Doser N, 389
Dourado I, 490

Downing R, 495
Drew WL, 320
Drobacheff C, 137
Dupont C, 151
Duwe S, 266

Easterbrook P, 462
Eholie S, 501
Emrick CB, 63
Engels EA, 371
Eron JJ, 458
Etzel A, 185
Eyre S, 63

Fang F, 1
Fenaughty KE, 515
Filho PB, 490
Fischer M, 397
Fisher DG, 515
Fisher M, 462
Folks TM, 93
Fong S, 56
Friedland GH, 118
Frisch M, 371
Fullem A, 21
Funk GA, 397
Furlan S, 332
Fusco GP, 72
Fusco JS, 72

Gadkari DA, 352
Galli L, 196
Galvão-Castro B, 490
Gangakhedkar RR, 352
Gange SJ, 28
Gazzard BG, 514
Gebel HM, 103
George K, 176
Gérard L, 182
Gilleece Y, 514
Gillini L, 326
Girardi E, 326
Goebel FD, 225
Goedert JJ, 371
Goetz MB, 390
Gold P, 8
Gomes MS, 300
Gomperts E, 466
González-Lahoz J, 391
Gradstein S, 111
Graham NMH, 72
Green MJ, 56
Green T, 93
Grosset J, 300
Gubler B, 303
Gueye NFN, 130
Günthard HF, 397
Gunzburg WH, 8
Gupta SM, 393

Haga T, 256
Hahn T, 111
Hammill H, 236
Hamouda O, 266
Handzel ZT, 111
Hänsel A, 191
Hansen NI, 72
Harbke CR, 515
Hashimoto H, 512
Haubrich R, 458
Haubrich R, S3, S51
Haumont P, 507
Hay P, 462
Hecht FM, 435
Hejal R, 305
Hemophilia Growth and Development Study, 466
Hendel H, 507
Heneine W, 93
Hertogs K, 145, 495, 501, 514
Hilgartner MW, 466
Hishikawa T, 512
Hittinger G, 44
Ho D, 332
Hofmann-Lehmann R, 8
Hollinger FB, 340
Hong L, 298
Hoots WK, 466
Huang C, 246
Huang K-L, 274
Hugen PWH, 218
Hughes MP, 360
Hurley A, 1, 332

Igboko EF, 72
Ippolito G, 326
Irwin CE, 208

Jacobson LP, 82
Jen I, 274
Jensen RH, 256
John GC, 170
Johnson J, 1, 332
Johnson M, 159
Jones L, 305
Joos B, 397
Jorge MLSG, 185
Joshi S, 21, 352

Kabugo M, 176
Kaldor JM, 283
Kalish LA, 320
Kalish M, 93
Kamya M, 176
Kaneko H, 512
Kaneko Y, 512
Kang S-Y, 164
Kaplan EH, 118
Kazatchkine MD, 193
Kebba A, 495
Kegeles S, 63
Kelly C, 21
Ketoff NR, 305
Khalilli K, 507
Khanani F, 63
Kim S-H, 256
Kingsley L, 82
Kityo CM, 495
Kleeberger CA, 82
Klein D, 8
Klein RS, 291
Kony S, 130
Kopicko J, 513
Kost R, 1
Kost RG, 332
Kostrikis LG, 298
Kpamegan E, 236
Kreiss J, 170
Kreiss JK, 360
Kücherer C, 266
Kumar PN, 320
Kumwenda N, 21
Kunches LM, 263
Kwiatkowski CF, 483

Lackritz E, 495
Lafeuillade A, 44
Lai S, 365
Lambert M, 303
Lan Y-C, 274
Landesman S, 236
Lang W, 458
Lange J, S1
Lange JMA, 218
Lanier R, 423
Lantz O, 303
Larder B, 495, 501
Laurent R, 137
Le Moing V, 151
Lebigot S, 413
Ledergerber B, 397
Lee F, 93
Leiser RJ, 443
Lemiale F, 413
Leport C, 480
Leutenegger CM, 8
Levine AM, 28
Lewden C, 480
Lewis K, 381
Li R-J, 365
Li Y, 283
Li Z-J, 365
Liang F-X, 365
Liang S-L, 365
Lièvre L, 130
Lin HJ, 340
Lindsey JC, 449
Liu W, 365
Liu Y-C, 274
Lo JC, 443
Lounis N, 300
Loveday C, S10
Lutz H, 8
Lynn H, 466

MacQueen KM, 63
Madge S, 159
Mafigiri D, 176
Maillard A, 182
Malach L, 111
Mandaliya K, 360
Margolis DM, 423
Markowitz L, 345
Markowitz M, 332
Markowitz MH, 1
Maron D, 170
Masri-Lavine L, 28
Mastro TD, 348
Matheron S, 151
Matsumoto T, 512
Mauger DT, 56
Maurice C, 501
Maynart M, 130
Mazzolla R, 300
Mbori-Ngacha D, 170
McDonald A, 283
McGarrigle C, 381
McGrath JW, 176
McGuire JF, 263
McKenna SM, 305
McLellan E, 63
Meehan TM, 263
Meenhorst PL, 218
Mehendale S, 21
Mehendale SM, 352
Meillet D, 137
Melby T, 423
Metro A, 130
Metzger D, 63
Michl GM, 225
Millard J, 458
Miller V, S34
Millon L, 137
Mintz L, 320
Mittler JE, 405
Moat C, 193
Mock P, 348
Mocroft A, 159
Monard S, 1
Monga B, 501
Monod M, 137
Montes B, 36
Moore AL, 159
Mooser V, 389
Moriondo M, 196
Mortimer PP, 381
Moss A, 435
Mostad SB, 360
Mugisha E, 176
Mugyenyi P, 495
Mulder JW, 218
Mulligan K, 443
Murphy G, 381

Naito T, 512
Nasti G, 299
Ndinya-Achola JO, 360
Ndoye I, 130
Nduati R, 170
Nelson G, 507
Nelson K, 21
Nelson PW, 405
Nesheim S, 93
Newman M, 28
Nicod P, 389
Nicoll A, 381
Nitayaphan S, 345
Nkengasong JN, 501
Nüesch R, 191
Nuñez M, 391

O'Brien M, 513
O'Brien S, 507
Ogasawara H, 512
Okada M, 512
Oksenhendler E, 182
Olinger GG, 103
Oller V, 391
Opravil M, 397
Overbaugh J, 360

Padian N, 21
Pagano G, 458
Palefsky JM, 256
Palmieri F, 326
Pappagallo M, 473
Para MF, 320
Parada JP, 390
Paranjape RS, 352
Parekh B, 348
Parry JV, 381
Pauli G, 266
Pedneault L, 458
Peeters M, 36, 501
Peguillet I, 303
Perelson AS, 405
Pérez-Olmeda M, 145
Perinatal AIDS Collaborative Transmission Studies (PACTS) members, 93
Perlis T, 164
Peruzzi M, 196
Petrosillo N, 326
Pezzotti P, 394, 473
Phair JP, 82
Phillips AN, 159, 473
Piarroux R, 137
Pieniazek D, 495
Pisapia M, 44
Pliner V, 93
Poggi C, 44
Pollard RB, 320
Pozniak A, 462
Pozniak AL, 514
Prins JM, 218

Raffanti SR, 72
Raffi F, 480
Rappaport J, 507
Ray K, 393
Read JS, 236
Reboux G, 137
Reiner M, 170
Reisler RB, 93
Reiss G, 513
Reiss P, 218
Respess R, 495, 501
Revel M, 111
Reynes J, 36
Rezza G, 377, 394, 473
Rich EA, 305
Risbud AR, 352
Rizzardini G, 299
Robles R, 164
Rodríguez C, 145
Rodríguez-Rosado R, 391
Roels TH, 501
Roemer-Binns E, 507
Rogers PA, 381
Roongpisuthipong A, 348
Rousseau M-N, 36
Rozman M, 185
Rugpao S, 21

Sabin CA, 462
Saha K, 199
Saifuddin M, 103
Salmons B, 8
Sanchez ML, 28
Sangtaweesin V, 348
Santos M, 490
Schambelan M, 443
Schmidt B, 266
Schmitz M, 225
Schulz TF, 182
Segondy M, 36
Segurado AAC, 185
Seidel D, 225
Sekigawa I, 512
Semba RD, 315, 352
Sengupta S, 63
Senvewo R, 176
Sepulveda C, 193
Serraino D, 377
Shaffer N, 348
Shah N, 315
Sheldon J, 182
Shepherd ME, 352
Sheppard H, 170
Shibata GY, 185
Shuter J, 291
SIDAK Study Group, 130
Simonds RJ, 348
Singhanati S, 348
Sinicco A, 473
Sipler AM, 390
Siriwasin W, 348
Slatko GH, 72
Smiley L, 1, 332
Smith Rogers A, 449
Snowden W, 458
Sobel A, 480

Soriano V, 145, 391
Soteriadou K, 300
Sow PS, 130
Spear GT, 103
Strathdee SA, 82
Strauss RP, 63
Sudre P, 389
Sukwit S, 345
Suligoi B, 377
Svilar G, 176

Taha T, 21
Tai VW, 443
Talal A, 332
Talal AH, 1, 208
Taoufik Y, 303
Taramelli D, 300
Tchetgen E, 118
Telenti A, 389
ten Veen JH, 218
Thea DM, 93
Thiakaki M, 300
Thompson B, 236
Tirelli U, 299, 377
Tisdale M, 458
Tognazioli C, 300
Toossi Z, 305
Torti C, 514
Trichavaroj R, 345
Trylesinski A, 303
Tsai J-J, 274
Tuomala R, 236
Turner D, 423

Ubel PA, 56

Vajaranant M, 236
Valadão E, 490
Valdarchi C, 394, 473
van de Wijgert J, 21
van der Meer JTM, 218
van der Poll T, 218
Vanprapar N, 348
Verbiest W, 501
Vergne L, 36
Verrier B, 413
Vesanen M, 1, 332
Vierucci A, 196
Vlahov D, 315
Volberding P, S1

Wagner TM, 394
Wallach FR, 320
Walli R, 225
Walter H, 266
Wang S, 246
Wasi C, 348
Watts H, 28
Weidle PJ, 495
Weinstein RA, 390
Weiss L, 193
Wietlisbach V, 389
Wiktor SZ, 501
Williams I, 462
Wilson D, 159
Winkler C, 507
Winkler CA, 466
Wolfram J, 458
Wong J-C, 274
Wong W-Y, 466
Wu M, 305

Yang J, 365
Yee H, 208
Young M, 28
Young N, 348
Yu X-F, 365

Zaccarelli M, 473
Zagury D, 507
Zagury J-F, 507
Zazzi M, 196
Zerhouni B, 199
Zhang J, 199
Zhang L, 208, 332
Zheng Z, 1
Zhu Q-Y, 365
Zinzi D, 326
Zorrilla C, 236

JAIDS Journal of Acquired Immune Deficiency Syndromes
26:521–528 © 2001 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 26, 2001

Subject Index

Abacavir, open-label phase II trial of, 332
ABI Prism 7700 Sequence Detection System, multiplex RT-PCR based on, 8
Adherence, to HIV antiretroviral therapy, 435
Adolescents, HIV-1 RNA levels and clinical disease development in, 449
Adult T-cell leukemia/lymphoma, in AIDS patients, 371
AF358746, HIV resistance to, 495
AF358760, HIV resistance to, 495
Africa
  antiretroviral resistance in, 495, 501
  developing AIDS vaccine trials educational programs in, 176
African-Americans, in HIV vaccine trials, 63
AIDS
  incidence of, adherence to HAART and, 118
  treatment, rationing of, 56
  vaccine trials educational programs for in Uganda, 176
  validation of genetic case-control studies in, 507
AIDS clinic, overweight in prognosis in, 291
AIDS-defining diseases
  in Australia, 283
  pattern of in HAART (letter), 394
AIDS-related opportunistic infections, chloroquine results in (letter), 300
Alloantibody, to major histocompatibility complex alloantigens, 103
Alloantigens, human antibodies to in HIV-1 lysis and neutralization, 103
Alloimmunization, antibodies to major histocompatibility complex alloantigens in, 103
Amp-RT-reverse transcriptase, in HIV-1-infected neonate plasma, 93
Amprenavir
  open-label phase II trial of, 332
  in phase II trials of dual protease inhbiitor therapy, 458
Anal cancer, genetic changes with, 256
Anal intraepithelial neoplasia, detecting genetic changes in, 256
Anemia
  in HIV-infected injection drug users receiving HAART, 315
  in HIV-infected women, 28
Anti-infective agents, phase I clinical trial of, 21
Antibodies, to major histocompatibility complex alloantigens, 103
Antiretroviral drugs
  genotypic and phenotypic resistance assays for, S3
  resistance mutations to, 36
Antiretroviral-naive HIV-positive patients, nevirapine treatment of, 462
Antiretroviral resistance
  analysis of in multidrug-resistant HIV-1 infection, 423
  mycophenolate mofetil in therapy in, 423
  predictors of, S51
Antiretroviral therapy
  combination
    apolipoprotein B metabolism and, 225
  determinants of heterogeneous adherence to, 82
  long-term failure of, S25
  Pneumocystis carinii pneumonia recurrence and, 151
  provider assessment of adherence to, 435
  public health consequences of screening for adherence to, 118
  reasons for failure of, S1
  resistance to
    among Ugandan patients, 495
    in Côte d'Ivoire, 501
  response to by duration of HIV infection, 473
Apolipoprotein B metabolism, in HIV-infected patients with antiretroviral combination therapy, 225
Asia
  HIV-1 incidence among heroin users in, 365
  temporal trends and molecular epidemiology of HIV-1 subtypes in, 274
Aspartic proteinases, secreted, 137
Australia, spectrum of AIDS-defining illnesses in, 283

BMS-232632, resistance to, S34
Body composition, with nucleoside analog reverse transcriptase inhibitors, 443
Body mass index, predictive value of in HIV care clinic, 291
Brazil
  human T-cell lymphotropic virus type I infection among pregnant women in, 490
  seroprevalence and risk factors for HTLV-1/2 in HIV-infected patients in, 185
BufferGel, phase I clinical trial of, 21
Burst-forming unit, erythroid (BFU-E) colonies, in hematopoiesis, 111

Candidiasis
  esophageal, in Australia, 283
  oropharyngeal, in HIV-infected patients, 137
Carotenoids, low concentration of and HIV seroconversion in Pune, India, 352

CCR5, HIV-1 replication through, 305
CCR2-64I alleles, in Tunisian population (letter), 298
CCR5Δ32 alleles, in Tunisian population (letter), 298
CD4 cell count
  alternative methods for in developing countries (letter), 193
  in antiretroviral-naive HIV-positive patients treated with nevirapine, 462
  Pneumocystis carinii pneumonia recurrence and, 151
  with zidovudine and stavudine sequencing, 72
$CD4^+$ T cells
  alternative methods for enumerating in developing countries (letter), 193
  in HIV-1 perinatally infected children (letter), 196
  proliferation of in GALT, 208
$CD8^+$ T cells
  in HIV-1 perinatally infected children (letter), 196
  productively infected in AIDS patients, 199
Cell compartments, HIV-1 viral replicative capacity in, 397
Cellular resistance, to protease inhibitors, S34
Cellular response, in multidrug-resistant HIV-1 infection, 423
Cervical cancer, incidence of in HIV-seropositive women before and after HAART, 377
Cervicovaginal secretions, HIV-1 RNA quantitation in, 170
Chemokine receptors
  curdlan sulfate inducing downmodulation of (letter), 512
  genetic case-control studies of, 507
β-Chemokines, dysregulation of in lungs of HIV-1-infected patients, 305
Children, $CD4^+$ and $CD8^+$ T lymphocyte recovery in (letter), 196
China, HIV-1 incidence among heroin users in, 365
Chloroquine, in AIDS-related opportunistic infections (letter), 300
Chronic disease, in HIV-infected injection drug users receiving HAART, 315
Clinical presentation, in HIV-associated tuberculosis after HAART, 326
Clinical procedures, for HIV-1 RNA detection and quantitation in cervicovaginal secretions, 170
Clinical trials
  for cotrimoxazole in primary prevention for HIV-1-infected patients, 130
  education programs for in Uganda, 176
Cohort studies, determinants of adherence to antiretroviral therapy in, 82
Collaborations in HIV Outcomes Research (CHORUS) HIV cohort study, zidovudine and stavudine sequencing in, 72
Combination therapy
  feasibility and efficacy of in chronic hepatitis C and HIV-coinfection (letter), 299
  HIV-1 viral replication and, 397
  for multidrug-resistant HIV-1 infection, 423
  in patients failing protease inhibitor-containing regimens (letter), 391
Comparative genomic hybridization, in detecting genetic changes with anal intraepithelial neoplasia, 256
Complement, in HIV-1 primary isolate virions and, 103
Côte d'Ivoire, antiretroviral resistance in, 501
Cotrimaxazole, in primary prevention for HIV-1-infected adults, 130
Cross-resistance
  to nonnucleoside reverse transcriptase inhibitors, S25
  to protease inhibitors, S34
Cryptococcosis, in Australia, 283
Curdlan sulfate, inducing downmodulation of chemokine receptors (letter), 512
CX3CR1 polymorphism, genetic case-control studies and, 507
Cytokines, with HAART, 44
Cytomegalovirus
  PCR measures of, 320
  related disease of in Australia, 283

Delhi, HIV antibodies in replacement blood donors in (letter), 393
Delivery mode, in postpartum morbidity among HIV-infected women, 236
Dementia, in nursing home residents with HIV, 246
Dermatitis, HTLV-1-associated infective, in pregnant women, 490
Developing countries, alternative CD4 cell count methods in (letter), 193
Diagnostic sensitivity, in HIV-1-infected neonates, 93
Disease duration, HAART response and, 473
Disease progression
  CX3CR1 polymorphism and, 507
  HIV-1 RNA levels and, 449
DNA amplification, in drug resistance assay, S3
Drug efficacy, in HIV viral dynamics, 405
Drug resistance
  adherence to HAART and, 118
  among Ugandan patients on antiretroviral therapy, 495
  clinical utility of testing for, S51
  with dissociation of responses to HAART (letter), 196
  effects of, S1
  genotypic and phenotypic, 266
  genotypic and phenotypic assays for, S3
  to nucleoside reverse transcriptase inhibitors, S10
  to protease inhibitors, S34
  in recent seroconverters, 145
Drug treatment, in HIV risk reduction, 483
Drug users, provider assessment of adherence to HIV antiretroviral therapy for, 435
Dual-energy X-ray absorptiometry (DEXA), showing altered fat distribution with nucleoside analog reverse transcriptase inhibitors, 443
Dual protease inhibitor therapy, phase II trial of, 458
Dyslipidemia, in HIV-infected individuals switched from protease inhibitor-containing to efavirenz-containing regimens (letter), 389

Economics, of HIV medication rationing, 56
Educational programs, for AIDS vaccine, 176
Efavirenz
  in combination therapy in patients failing protease inhibitor-containing regimens (letter), 391
  persistent dyslipidemia in individual switched to regimens containing (letter), 389
  resistance to, S25
Efficacy, of twice-daily indinavir-ritnoavir combinations, 218

Emergency departments, nonoccupational HIV postexposure prophylaxis in, 263
England, surveillance of HIV-1 subtypes in, 381
Epidemiology
of antiretroviral resistance in Africa, 501
of human T-cell lymphotropic virus type I infection in pregnant women in pregnant women in Brazil, 490
Erratum: "Patterns of Resistance Mutations to Antiretroviral Drugs in Extensively Treated HIV-1-Infected Patients with Failure of Highly Active Antiretroviral Therapy" (26:36-43), 395
Ethics, of HIV medication rationing, 56

Fat distribution, altered in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy, 443
Feline immunodeficiency virus, multiplex RT-PCR for, 8
Female genital tract, HIV-1 cell shedding in with selenium deficiency, 360
Female sex workers, temporal trends and molecular epidemiology of HIV-1 subtypes in, 274
Fitness, in nonnucleoside reverse transcriptase inhibitor resistance, S25
Fluorogenic probes, in multiplex RT-PCR, 8

Gastrointestinal adverse events, during pregnancy in women prescribed nelfinavir (letter), 513
Gastrointestinal system, lymphocyte proliferation in, 208
Gay men, in HIV vaccine trials, 63
Gender, in virologic response to HIV treatment, 159
Genetic case-control studies, validation of, 507
Genetic changes, in anal intraepithelial neoplasia, 256
Genetics of the Resistance to Infection by the Immunodeficiency Virus (GRIV) study, validation of, 507
Genital secretions, HIV-1 RNA quantitation in, 170
Genotype assays, for drug resistance, S1, S3
Genotypic HIV-1 drug resistance
frequency of in therapy-naive patients, 266
in seroconverters, 145
Genotypic resistance
in HAART failure, 36
prevalence of in Côte d'Ivoire, 501
Genotypic resistance assays
clinical utility of, S51
interpretation of, S10
Geographic variation, in AIDS-defining illnesses in Australia, 283
Granulomonocytic colony-forming cells (GM-CFC), in hematopoiesis, 111
Gut-associated lymphoid tissue
antiretroviral therapy effects on HIV-1 in, 1
HIV-1 infection effect on lymphocyte proliferation in, 208

Health care provider, assessment of adherence to HIV antiretroviral therapy, 435
Health care rationing, for HIV, 56
Health policy, on HIV medication rationing, 56
Hematopoiesis, recombinant TNF-alpha binding protein in, 111
Hemoglobin, in HIV-infected injection drug users receiving HAART, 315
Hemophilia Growth and Development Study, HIV-1 RNA levels and, 449
Hepatitis B virus, HIV-1 infection coexisting with, 340
Hepatitis C virus
chronic, in HIV-coinfected patients (letter), 299
in hemophilia patients, 466
and HIV-1 incidence in China, 365
HIV-1 infection coexistence with, 340
Heroin users, HIV-1 incidence among in China, 365
Heterosexual transmission
of HIV-1 subtypes in England and Wales, 381
of HIV-1 subtypes in Taiwan, 274
Highly active antiretroviral therapy (HAART)
AIDS-defining diseases in persons responding to (letter), 394
changing clinical presentation and survival in HIV-associated tuberculosis after, 326
with cytokines to induce HIV-1 remission, 44
dissociation of responses to (letter), 196
effects on HIV-1 in GALT, 1
gender differences in virologic response to, 159
improvement of anemia among HIV-infected injection drug users receiving, 315
in interleukin-10 and interleukin-12 expression, 303
invasive cervical cancer and, 377
mortality in HIV-infected cohort started on, 480
Pneumocystis carinii pneumonia recurrence in, 151
provider assessment of adherence to, 435
public health consequences of screening for adherence to, 118
reasons for discontinuing in proteinase inhibitor-naive HIV-infected patients (letter), 191
resistance mutations in failure of, 36
response to by duration of HIV infection, 473
HIV-1 DNA
with HAART and cytokines, 44
reverse transcriptase activity and in neonate plasma, 93
HIV-1 genotypic resistance, with HAART failure, 36
HIV-1-infected cell shedding, selenium deficiency and, 360
HIV-1 infection
β-chemokine dysregulation in lungs in, 305
in diagnosis and evaluation of hepatitis C virus, 340
HAART and cytokines to induce remission of, 44
hepatitis C viral load and in hemophilia patients, 466
incidence of in heroin users in China, 365
lymphocyte proliferation in GALT and, 208
multidrug-resistant, mycophenolate mofetil in therapy for, 423
in neonates, reverse transcriptase activity in plasma of, 93
open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in, 332
pathogenesis of
hepatitis C viral load and in hemophilia patients, 466
productively infected $CD8^+$ T cells in AIDS patients and, 199
primary prevention with cotrimaxazole in, 130
seroprevalence and risk factors for HTLV-1/2 in, 185
HIV-1 isolate virions, MHC alloantibodies in lysis and neutralization of, 103
HIV-1 replication, quantification of in different cell compartments, 397

HIV-1 RNA
in clinical disease in adolescent populations, 449
with HAART and cytokines, 44
techniques for detection and quantitation of in cervicovaginal secretions, 170
in Thai men and women with subtype E infections, 345
with zidovudine and stavudine sequencing, 72
HIV-1 subtypes
national surveillance of, 381
temporal trends and molecular epidemiology of in Taiwan, 274
HIV-1 tropism, pathogenesis and, 199
HIV antibodies, in replacement blood donors (letter), 393
HIV antiretroviral therapy
determinants of heterogeneous adherence to, 82
provider assessment of adherence to, 435
HIV-associated lymphoma, human herpesvirus 8 seroprevalence in, 182
HIV care clinic, overweight and prognosis in, 291
HIV-chronic hepatitis C coinfection (letter), 299
HIV drug resistance
among Ugandan patients on antiretroviral therapy, 495
in Côte d'Ivoire, 501
HIV infection
anemia prevalence in women with, 28
curdlan sulfate inducing downmodulation of chemokine receptors in suppression of (letter), 512
dementia and in nursing home residents, 246
pathogenesis of, drug efficacy and eclipse phase of viral life cycle in, 405
HIV postexposure prophylaxis, nonoccupational, 263
HIV prevention, phase I clinical trial of BufferGel in, 21
HIV Prevention Trials Network (NIVNET), 63
HIV risk reduction, methadone maintenance as, 483
HIV RNA, in antiretroviral-naive HIV-positive patients treated with nevirapine, 462
HIV seroconversion
invasive cervical cancer and, 377
low carotenoid concentration and risk of, 352
HIV seroconverters, response to HAART in, 473
HIV seroprevalence, needle sharing and, 164
HIV subtypes
drug resistance of, 495
resistance to antiretroviral therapy in Côte d'Ivoire, 501
HIV transmission, primary genotypic and phenotypic HIV-1 drug resistance and, 145
HIV treatment
gender differences in virologic response to, 159
zidovudine and stavudine sequencing in, 72
HIV vaccine
educational programs for, 176
willingness to volunteer in trials for, 63
HIV viral dynamics, drug efficacy and eclipse phase of viral life cycle in, 405
HIV viral load, in Thai men and women with subtype E infections, 345
HLA, in HIV-1 immunization, 103
Homeless, provider assessment of adherence to HIV antiretroviral therapy for, 435
Hospital emergency departments, nonoccupational HIV postexposure prophylaxis in, 263
Human herpesvirus 8, seroprevalence for in HIV-associated non-Hodgkin's lymphoma patients, 182
Human papillomavirus, genetic changes with, 256
Human T-cell lymphotropic virus type 1 (HTLV-1) infection
in pregnant women in Brazil, 490
seroprevalence and risk factors for, 185
Human T-cell lymphotropic virus type 2 (HTLV-2) infection, seroprevalence and risk factors for, 185
Hypertriglyceridemia, apolipoprotein B metabolism and, 225

IC_{50}, in drug resistance assay, S3
Immune intervention, with HAART and cytokines, 44
Immunogenicity, of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates, 413
Immunology, of HAART on HIV-1 in GALT, 1
India
HIV antibodies in replacement blood donors in (letter), 393
low carotenoid concentration and risk of HIV seroconversion in, 352
Indinavir
in phase II trials of dual protease inhibitor therapy, 458
twice-daily regimen of, 218
Informed consent, for AIDS vaccine trials, 176
Injection drug users
HIV-1 subtypes in, 274
HIV seroprevalence and needle sharing among, 164
in HIV vaccine trials, 63
improvement of anemia with HAART among, 315
methadone maintenance as HIV risk reduction in, 483
provider assessment of adherence to HIV antiretroviral therapy for, 435
syringe type preference among (letter), 515
Insulin resistance, apolipoprotein B metabolism and, 225
Interferon-α2b, feasibility and efficacy of in chronic hepatitis C and HIV-coinfection (letter), 299
Interleukin-2, with HAART to induce HIV-1 remission, 44
Interleukin-10, HAART effect on expression of, 303
Interleukin-12, HAART effect on expression of, 303
Intestinal mucosa
antiretroviral therapy effects on HIV-1 in, 1
HIV-1 infection effect on lymphocyte proliferation in, 208
Invasive cervical cancer, incidence of in HIV-seropositive women before and after HAART, 377

Ki-67 antigen, in lymphocyte proliferation in GALT, 208
Kinetic modeling, of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy, 225

Lamivudine
HIV resistance to in Uganda, 495
open-label phase II trial of, 332
resistance to, S10
Latin America
human T-cell lymphotropic virus type I infection in pregnant women in, 490
seroprevalence and risk factors for HTLV-1/2 in HIV-infected patients in, 185

Letters to editor
chronic hepatitis C in HIV-coinfected patients: feasibility and efficacy of interferon-α2b and ribavirin combination therapy, 299
comparative assessment of five alternative methods for $CD4^+$ T-lymphocyte enumeration for implementation in developing countries, 193
contrasting frequencies of *CCR5Δ32* and *CCR2-641* alleles in the Tunisian population, 298
curdlan sulfate induces the downmodulation of chemokine receptors leading to suppression of HIV infection, 512
different pattern of AIDS-defining diseases in persons responding to highly active antiretroviral therapy, 394
dissociation of responses to HAART: notwithstanding virologic failure and virus drug resistance, 196
experimental results on chloroquine and AIDS-related opportunistic infections, 300
lack of association between pregnancy and selected gastrointestinal adverse events among women prescribed nelfinavir, 513
performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens, 390
persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen, 389
prevalence of HIV antibodies in replacement blood donors in Delhi, India, 393
reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients, 191
R211K and L214F do not invariably confer high level phenotypic resistance to thymidine analogs in zidovudine-naive patients with M184V, 514
syringe type preference among injection drug users, 515
variations in institutional review board decisions for HIV quality of care studies: a potential source of study bias, 390
L214F, phenotypic resistance to thymidine analogs with (letter), 514
Lipodystrophy, with nucleoside analog reverse transcriptase inhibitors, 443
Long-term follow-up, of antiretroviral-naive HIV-positive patients treated with nevirapine, 462
Longitudinal study, of anti-*Candida albicans* mucosal immunity against aspartic proteinases in HIV-infected patients, 137
Lopinavir, resistance to, S34
Lungs, β-chemokine dysregulation in, 305
Lymphocytes
HIV-1 infection effect on proliferation of, 208
productively infected in HIV-1 patients, 199
Lymphomas, risk of in AIDS patients, 371

Macrophage inflammatory protein (MIP-1α), dysregulation of in lungs of HIV-1-infected patients, 305
Macrophage inflammatory protein (MIP-1β), dysregulation of in lungs of HIV-1-infected patients, 305
Madrid, primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in, 145
Maintenance prophylaxis, *Pneumocystis carinii* pneumonia recurrence and, 151
Major histocompatibility complex alloantigens, human antibodies to in HIV-1 lysis and neutralization, 103
Mathematical models
for adherence to HAART, 118
for drug efficacy and eclipse phase of viral life cycle, 405
for HIV-1 viral replicative capacity in different cell compartments, 397
Medication adherence
determinants of, 82
public health consequences of screening for, 118
Methadone maintenance, as HIV risk reduction with injecting drug users, 483
Microbicides, phase I clinical trial of, 21
Minimum data set, in analysis of dementia in nursing home residents with HIV, 246
Molecular epidemiology
of HIV-1 infection in Taiwan, 274
of HIV-1 subtypes in England and Wales, 381
Monocyte chemotactic protein (MCP)-1, dysregulation of in lungs of HIV-1-infected patients, 305
Mortality, in HIV-infected cohort started on a protease inhibitor-containing therapy, 480
Mother-to-infant transmission
delivery mode and, 236
HIV seroconversion during pregnancy and, 348
Mucosal immunity, anti-*Candida albicans*, 137
Multicenter AIDS cohort studies, determinants of adherence to antiretroviral therapy in, 82
Multidrug-resistant HIV-1 infection, mycophenolate mofetil in therapy for, 423
Multiple-drug resistance, international perspective on, S10
Mutations
in antiretroviral drug resistance with HAART failure, 36
interactions between, S34
in resistance to nonnucleoside reverse transcriptase inhibitors, S25
in reverse transcriptase inhibitor resistance, S10
M184V mutation
in antiretroviral resistance, S10
R211K and L214F in phenotypic resistance to thymidine analogs with (letter), 514
Mycobacterium avium complex infection, in Australia, 283
Mycophenolate mofetil, in multidrug-resistant HIV-1 infection therapy, 423
Mycophenolic acid, in multidrug-resistant HIV-1 infection therapy, 423
Mycosis fungoides, in AIDS patients, 371

Needle sharing, HIV seroprevalence and, 164
Nelfinavir
in combination therapy in patients failing protease inhibitor-containing regimens (letter), 391
in gastrointestinal adverse events during pregnancy (letter), 513
in phase II trials of dual protease inhbiitor therapy, 458
Neonates, reverse transcriptase activity in plasma of, 93
Nevirapine
antiretroviral-naive HIV-positive patients treated with, 462
resistance to, S25

New York, needle sharing and HIV seroprevalence among injection drug users in, 164
Non-Hodgkin's lymphoma
in AIDS patients, 371
HIV-associated, human herpesvirus 8 seroprevalence in, 182
Nonnucleoside reverse transcriptase inhibitors, resistance to, S25
Nucleic acid sequence-based amplification, in HIV-1-infected neonates, 93
Nucleoside reverse transcriptase inhibitors
altered fat distribution with, 443
resistance to, S10
sequencing of in HIV treatment plans, 72
Nursing home residents, with HIV and dementia using minimum data set, 246
Nutritional deficiency, HIV-1 cell shedding and, 360

Obstetrics, HTLV-1 infection in, 490
Opportunistic infections, chloroquine results in (letter), 300
Oropharyngeal candidiasis, in HIV-infected patients, 137
Overweight, in prognosis in urban HIV care clinic, 291

Pathogenesis, T cell infection and, 199
Perinatal transmission
HIV seroconversion during pregnancy and, 348
virologic failure and HAART resistance with (letter), 196
Pharmacokinetics, of twice-daily indinavir-ritnoavir combinations, 218
Phase I trial
of topical microbicide BufferGel, 21
Phase II trial
of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine, 332
of dual protease inhibitor therapy, 458
Phenotype resistance assays, S1, S3
Phenotypic resistance
HIV-1 drug
frequency of in therapy-naive patients, 266
in seroconverters, 145
prevalence of in Côte d'Ivoire, 501
R211K and L214F in (letter), 514
Phenotypic resistance assays
clinical utility of, S51
Pneumocystis carinii pneumonia, recurrence of in HIV patients on HAART, 151
Point mutations, in resistance to nonnucleoside reverse transcriptase inhibitors, S25
Polymerase chain reaction
for cytomegalovirus in HIV-infected patients requiring transfusions, 320
real-time, multiplex, for FIV, 8
reverse transcriptase activity for in HIV-1-infected neonates, 93
Polymorphism, genetic case-control studies and, 507
Postpartum morbidity, delivery mode and among HIV-infected women, 236
Pregnancy
gastrointestinal adverse events and in women prescribed nelfinavir (letter), 513
HIV seroconversion during, 348
human T-cell lymphotropic virus type I infection during, 490
Prevention
with cotrimaxazole, 130
willingness to volunteer in HIV vaccine trials for, 63
Primary HIV isolates, recombinant envelope glycoproteins derived from, 413
Prognosis
in HIV-1-infected neonates, 93
overweight in urban HIV care clinic, 291
Prophylaxis, HIV postexposure, in hospital emergency departments, 263
Protease inhibitors
altered fat distribution with, 443
apolipoprotein B metabolism and, 225
dual therapy of, phase II trials of, 458
improved anemia with, 315
mortality in HIV-infected cohort started on, 480
in multidrug-resistant HIV-1 infection therapy, 423
persistent dyslipidemia in individual switched from (letter), 389
quadruple combination performance in patients failing regimens containing (letter), 391
resistance to, S34
Public health, screening patients for HAART adherence and, 118
Public policy, on HIV medication rationing, 56
Puerto Rico, needle sharing and HIV seroprevalence among injection drug users in, 164

Quadruple combination therapy, in patients failing protease inhibitor-containing regimens (letter), 391
Quality of care, institutional review board decisions in (letter), 390
Quality of life, in advanced HIV patients requiring transfusions, 320

RANTES, dysregulation of in lungs of HIV-1-infected patients, 305
Rash, nevirapine-associated, 462
Rationing, of HIV medications, 56
Recombinant envelope glycoproteins, immunogenicity of, 413
Recombinant tumor necrosis factor-alpha binding protein, in hematopoiesis of HIV-infected patients, 111
Replacement blood donors, HIV antibodies in (letter), 393
Reproductive rate, of HIV-1 virus, 397
Research participation, in HIV vaccine trials, 63
Residual viral pool, with HAART and cytokines, 44
Resistance assays
clinical utility of, S51
interpretation of, S1
phenotypic and genotypic, S3
Resistance mutations
among Ugandan patients on antiretroviral therapy, 495
to antiretroviral therapy in Côte d'Ivoire, 501
Reverse transcriptase activity, early detection of in HIV-1-infected neonate plasma, 93
Reverse transcriptase enzyme, resistance to, S10

Reverse transcriptase inhibitors, nonnucleoside, resistance to, S25
Ribavirin, feasibility and efficacy of in chronic hepatitis C and HIV-coinfection (letter), 299
Risk factors
for HIV-1 in China, 365
in HIV seroprevalence among injection drug users, 164
for HTLV-1/2 in HIV-infected patients, 185
for *Pneumocystis carinii* pneumonia recurrence, 151
Ritonavir, twice-daily regimen of, 218
R211K, phenotypic resistance to thymidine analogs with (letter), 514

Safety, of twice-daily indinavir-ritnoavir combinations, 218
Sap antigens, secreted, 137
Saquinavir, in phase II trials of dual protease inhbiitor therapy, 458
Screening programs, for adherence to HAART, 118
Selenium deficiency, HIV-1-infected cell shedding with, 360
Senegal, cotrimoxazole in primary prevention for HIV-1-infected patients in, 130
Sequencing, in drug resistance, S3
Seroconversion
invasive cervical cancer and, 377
low carotenoid concentration and risk of, 352
during pregnancy and risk for mother-to-infant transmission, 348
Seroconverters
genotypic and phenotypic drug resistance in, 266
primary genotypic and phenotypic HIV-1 drug resistance in, 145
Seroprevalence
among injection drug users, 164
of HIV-1 infection coexisting with hepatitis C virus, 340
of HTLV-1/2 in HIV-infected patients, 185
of human herpesvirus 8 in HIV-associated non-Hodgkin's lymphoma patients, 182
Spain, primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in, 145
Specimen collection techniques, for HIV-1 RNA quantitation in cervicovaginal secretions, 170
Spermicides, phase I clinical trial of, 21
Stavudine, sequencing in HIV treatment planning, 72
Surveillance, of HIV-1 subtypes in England and Wales, 381
Survival, with HIV-associated tuberculosis after HAART, 326
Syncitium, in $CD8^+$ T cells, 199
Syringe type preference, among injection drug users (letter), 515

T cell activation antigens, in GALT, 208
T cell counts
alternative methods for in developing countries (letter), 193
in HIV-1 perinatally infected children (letter), 196
T-cell line-adapted isolates, recombinant envelope glycoproteins derived from, 413
T-cell lymphomas, risk of in AIDS patients, 371
Taiwan, temporal trends and molecular epidemiology of HIV-1 subtypes in, 274
TaqMan, multiplex RT-PCR based on, 8
Thailand
HIV seroconversion during pregnancy in, 348
HIV viral load in subtype E infected people in, 345
Therapy-naive seroconverters, genotypic and phenotypic drug resistance in, 266
Therapy standardization, mortality and, 480
Thymidine analogs, R211K and L214F in phenotypic resistance to (letter), 514
Tipranavir, resistance to, S34
Transfusions, PCR measures of cytomegalovirus in HIV-infected patients requiring, 320
Transmission
delivery mode and postpartum morbidity with, 236
of HIV-1 subtypes
in England and Wales, 381
in Taiwan, 274
HIV seroconversion during pregnancy and, 348
primary genotypic and phenotypic HIV-1 drug resistance and, 145
selenium deficiency and, 360
Treatment effectiveness, duration of HIV infection and, 473
Treatment failure
in HIV-1 perinatally infected children (letter), 196
reasons for, S1
resistance mutations to antiretroviral drugs in, 36
Treatment response, predictors of, S51
Tuberculosis, HIV-associated
in Australia, 283
changing clinical presentation and survival in, 326
Tumor necrosis factor-alpha, in hematopoiesis of HIV-infected patients, 111
Tunisia, *CCR5Δ32 and CCR2-64I* alleles in (letter), 298

Uganda
developing AIDS vaccine trials educational programs in, 176
resistance to antiretroviral therapy in, 495

Vaccine trials
education programs for
in Uganda, 176
willingness to volunteer in, 63
Vaginal secretions, HIV-1 RNA quantitation in, 170
Vaginal spermicide, phase I clinical trial of, 21
Viral Activation Transfusion Study (VATS), PCR measures of cytomegalovirus and, 320
Viral dynamics, in different cell compartments, 397
Viral fitness
in HIV-1 viral replication, 397
in protease inhibitor resistance, S34
Viral life cycle, eclipse phase of, in HIV viral dynamics, 405
Viral load
disease progression and in adolescents, 449
with dissociation of responses to HAART (letter), 196
gender differences in, 159
with HAART and cytokines, 44
hepatitis C and in hemophilia patients, 466
nelfinavir plus efavirenz in naive subjects with (letter), 391

preassay and sequence variation effects on, 8
reverse transcriptase activity and in HIV-1-infected neonates, 93
risk factors with coexisting HIV-1 and hepatitis C virus, 340
in Thai men and women with subtype E infections, 345
Viral pool, with HAART and cytokines, 44
Viral replication, quantification of in different cell compartments, 397
Viral resistance, to protease inhibitors, S34
Viral shedding, selenium deficiency and, 360
Viral transmission, nonnucleoside reverse transcriptase inhibitor resistance and, S25
Virologic failure, with protease inhibitor resistance, S34
Virologic response
in antiretroviral-naive HIV-positive patients treated with nevirapine, 462
resistance testing and, S51
Virology
gender differences in, 159
of HAART on HIV-1 in GALT, 1
Vitamin A, risk of HIV seroconversion and, 352
Voluntary participants, in HIV vaccine trials, 63

Wales, surveillance of HIV-1 subtypes in, 381
Wasting syndrome, with nucleoside analog reverse transcriptase inhibitors, 443
Women
anemia prevalence and correlates with HIV infection in, 28
delivery mode and postpartum morbidity among HIV-infected, 236
pregnancy and gastrointestinal adverse events in with nelfinavir (letter), 513

Zidovudine
HIV resistance to in Uganda, 495
sequencing in HIV treatment planning, 72
Zidovudine/lamivudine
open-label phase II trial of, 332
resistance to, S10